Clinical Trial Update: VE303 for Prevention of Recurrent Clostridioides Difficile Infection [Phase 3]

View source ↗

Summary

Phase 3 clinical trial VE303 to prevent recurrence of Clostridioides difficile infection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• VE303

Snippet

Sponsor: Vedanta Biosciences, Inc. | Conditions: Clostridium Difficile, Clostridium Difficile Infections | Phase 3 | Status: RECRUITING